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Abstract
Introduction: Faecal calprotectin (FC) is a routinely used marker for identifying and monitoring children with inflammatory bowel disease (IBD). 
This non-invasive test is useful for screening children with gastrointestinal symptoms to avoid unnecessary invasive procedures. In this study, we va-
lidated for the first time the performance of a fully automated particle-enhanced turbidimetric immunoassay (PETIA) on the VITROS® 5600 analyzer 
for measurement of FC in symptomatic children and adolescents.
Materials and methods: For performance validation of the PETIA (fCAL® turbo, Bühlmann Laboratories, Switzerland) on the VITROS® 5600 analyzer 
(Ortho Clinical Diagnostics, USA) limit of quantitation (LoQ), linearity, precision data and calibration curve stability were defined. Additionally, 95 
faecal samples were measured using the PETIA, an enzyme-linked immunosorbent assay (ELISA; fCAL®, Bühlmann Laboratories, Switzerland) and a 
semi-quantitative lateral flow assay (Quantum Blue Reader®, Bühlmann Laboratories, Switzerland) for agreement evaluation. 
Results: The LoQ for calprotectin using PETIA on the VITROS® 5600 analyzer was 21 µg/g. The linearity range was 20 - 2100 µg/g and the precision study 
showed a total coefficient of variation (CV) between 2.3% and 8.9%. The calibration curve was stable for 4 weeks. Using the clinical samples quantifiable 
by PETIA, ELISA and the semi-quantitative lateral flow assay, Passing-Bablok regression analysis and Bland-Altman plots showed good agreement.
Conclusions: Due to good performance characteristics and agreement with established methods, the fully automated PETIA on the routine chemi-
stry analyzer VITROS® 5600 is a new analytical option for the rapid determination of FC.
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Faecal calprotectin (FC) is a routinely used marker 
for identifying and monitoring children with in-
flammatory bowel disease (IBD). This non-invasive 
test is very useful for screening children with gas-
trointestinal symptoms and differentiating organic 
from functional intestinal disorders, to avoid un-
necessary invasive procedures. The gold standard 
for diagnosis of IBD, endoscopic evaluation with il-
eocolonoscopy, can be very traumatizing, espe-
cially for children. Calprotectin, a 36 kDa protein, is 
predominantly located in the cytosol of neutrophil 
granulocytes (1). Besides, it is found in small parts 
in the cytosol of monocytes and macrophages, 
supporting the theory of having bactericidal and 
fungicidal properties (2). It is a marker of increased 
granulocyte turnover and consequently it is in-
volved in the regulation of inflammatory reactions. 
Literature reported elevated calprotectin concen-
trations in plasma, synovial fluid, urine and faeces 
in inflammatory state (3). As it is upregulated in in-
flammatory gastrointestinal (GI) diseases, FC is 
used as diagnostic biomarker in the detection and 
observation of chronic inflammatory bowel dis-
eases (IBD), for more than 10 years (2–5). 
In paediatrics, FC is commonly used in the detec-
tion of newly active IBD, in monitoring of therapy 
success as well as in the prediction of relapse in IBD 
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patients (6–9). With implementation of FC as bio-
marker in discriminating between functional and 
organic BD, the number of endoscopies has suc-
cessfully been reduced in paediatrics (10). In addi-
tion, it is a very resistant protein and therefore a sta-
ble parameter for laboratory testing, as collected 
faeces can be sent to a laboratory and stored up to 
7 days at room temperature prior to analysis (11,12). 
In healthy adult patients, FC concentrations < 50 
µg/g faeces is considered to be normal, concentra-
tions between 50 and 100 µg/g are treated as bor-
derline while concentrations > 100 µg/g need more 
precise intervention and deeper clinical workup 
(13). Importantly, FC concentrations have been 
shown to vary with age, the highest concentrations 
reported in new-borns (14–17).
The initial procedure for measuring FC was to per-
form an enzyme-linked immunosorbent assay (ELI-
SA). Disadvantage of this method is the long turna-
round time, as a batch contains around 35-40 sam-
ples and, in reality, analysis is not started until a 
batch is full. For point-of-care (POC) diagnostics of 
single sample testing in short time (minutes), quan-
titative and semi-quantitative methods were es-
tablished, but with the downside of a loss in accu-
racy compared to ELISA tests. For that reason, com-
panies developed and launched new fully auto-
mated immunochemical methods with short test-
turnaround times on existing routine chemistry 
analysers. Quite a number of laboratories use the 
VITROS® 5600 analyzer, due to its small sample size 
needed, which is highly advantageous in paediat-
ric settings. Therefore, we aimed to validate, for the 
first time, the recently launched Bühlmann fCAL® 
turbo particle-enhanced turbidimetric immunoas-
say (PETIA) for FC measurement on the VITROS® 
5600 analyzer.  
Materials and methods
Study design and subjects
Children and adolescents presenting to the ambu-
lance of our hospital with gastrointestinal symp-
toms, were enrolled and retrospectively investi-
gated for method validation at the paediatric lab-
oratory of the Medical University of Vienna from 
November 2016 to April 2017. Subjects were in-
cluded into investigation with the prerequisite of a 
doctor ordering a test for faecal calprotectin. 
Symptoms suggesting a test for intestinal disease 
included chronic diarrhoea, weight loss, abdomi-
nal pain, and cramping and/or mucous or bloody 
stool. A total of 95 stool samples of symptomatic 
children and adolescents were included, 56% 
males (N = 53) and 44% females (N = 42), with me-
dian age 10 years (range: 4 months – 18 years). The 
study was performed in accordance with the ethical 
principles of the Declaration of Helsinki and was ap-
proved by the local ethics committee (Ethics Com-
mittee of the Medical University of Vienna). 
Methods
Next to performance validation (which included 
limit of quantitation (LoQ), calibration curve stabil-
ity, linearity and precision study) of the new PETIA 
(fCAL® turbo, Bühlmann Laboratories, Switzerland) 
on the VITROS® 5600 Integrated System (Ortho 
Clinical Diagnostics, New Jersey, USA), faecal cal-
protectin concentration measurements were com-
pared to concentration values analysed by an ELI-
SA test (fCAL®, Bühlmann Laboratories, Switzer-
land) and a semi-quantitative lateral flow assay 
(Quantum Blue Reader®, Bühlmann Laboratories, 
Switzerland). Therefore, FC concentrations in fro-
zen faecal extracts were measured in duplicates 
by means of three different quantification meth-
ods. Diagnoses of ulcerative colitis (UC) and 
Crohn’s disease (CD) were confirmed by ileocolo-
noscopy and histology. 
Sample extraction and preparation
Stool samples were extracted using the CALEX® 
Cap device (Bühlmann Laboratories, Switzerland) 
according to the manufacturer’s instructions for 
sample preparation. Briefly, faecal samples were 
vortexed for 30 seconds and left for 10 minutes 
prior to analysis with the semi-quantitative lateral 
flow assay. After the initial determination with the 
semi-quantitative lateral flow assay for clinical pur-
pose, faecal extracts were frozen at − 20°C. The 
anonymous frozen extracts, analysed for routine 
work, were then used for the validation of the PE-
TIA on the VITROS® 5600 Integrated system. There-
fore, thawed faecal extracts were analysed in du-
https://doi.org/10.11613/BM.2017.030710 Biochem Med (Zagreb) 2017;27(3):030710 
  3
Noebauer B. et al. Fully automated PETIA for faecal calprotectin
plicates by the PETIA on VITROS® 5600, with an ELI-
SA test and the semi-quantitative lateral flow as-
say. For measurement with the PETIA and ELISA, 
the stool samples were additionally centrifuged 
for 10 min at 3000xg.
Regardless of the assay used for FC concentration 
measurement, all patient samples were measured 
in duplicates under same preanalytical conditions, 
using the arithmetic mean, for reflecting the im-
precision for patient samples. 
Quantum Blue Reader® 
The point-of-care (POC) Quantum Blue Reader® 
test is a semi-quantitative lateral flow immunoas-
say based on ELISA techniques. For performing 
the Quantum Blue Reader® test, manufacturer’s in-
structions were followed. Briefly, a 60 µL aliquot of 
a single extraction sample was pipetted onto the 
test cartridge to allow lateral migration. After an 
incubation time of 12 minutes, absolute FC values 
were automatically generated and presented as 
µg/g in the dynamic range of 30 - 1000 µg/g. 
Particle-enhanced turbidimetric immunoassay 
The novel PETIA was performed on the VITROS® 
5600 Integrated System. The reagent kit (B-KCAL-
RSET, fCAL® turbo, Bühlmann, Switzerland) con-
tains a Reaction Buffer (R1) and Immunoparticles 
(R2). Human calprotectin from granulocyte ex-
tracts in Bühlmann extraction buffer was used to 
achieve six different calibrator levels (B-KCAL-CA-
SET, fCAL® turbo Calibrator Kit, Bühlmann, Switzer-
land) as follows: 0, 52, 205, 509, 1023 and 2046 
μg/g, respectively. The calprotectin concentration 
of the calibrator was assigned via a value transfer 
protocol toward Bühlmann fCAL® ELISA. Controls 
(B-KCAL-CONSET, fCAL® turbo Control Kit, Bühl-
mann Switzerland) were prepared by adding hu-
man calprotectin from granulocyte extracts into 
Bühlmann extraction buffer, resulting in final con-
centrations of 75 μg/g (low) and 250 μg/g (high), 
respectively. A set of parameter settings was opti-
mized for the immunoassay on VITROS® 5600, be-
ing as follows:
•	 Sample volume (μL): 10
•	 R1 volume (μL): 130.0
•	 R2 volume (μL): 26.0
•	 Primary/secondary wavelength (nm): 575, and 
•	 Reading times (s): first reading 114 and second 
reading 175.75.
Enzyme-linked Immunosorbent Assay 
For performing the Bühlmann fCAL® ELISA, manu-
facturer’s instructions were followed as briefly 
summarized. After centrifugation of the prepared 
extract, for 10 minutes at 3000xg, the supernatant 
was diluted 1:50 with incubation buffer. A volume 
of 100 µL of the diluted supernatant was then 
transferred to an antibody-precoated ELISA plate 
and incubated for 30 minutes at room tempera-
ture. After a washing step, 100 µL of enzyme label 
was added prior to an additional 30 minutes incu-
bation step. Additionally, 100 µL of substrate was 
pipetted to the 100 µL of enzyme label and incu-
bated for another 15 minutes, protected from 
light. The optical density values were read at 450 
nm on a spectrophotometer.
Validation of PETIA on the VITROS® 5600 Integrated 
System
Limit of quantitation 
Limit of quantitation was defined as the lowest ac-
tual amount of the analyte that could be reliably 
detected with a total error below 20%. To assess 
the LoQ, a sample with an assigned value of 84 
µg/g was diluted (1:4, 1:5 and 1:6, respectively) 
with extraction buffer, supplied from the manu-
facturer, for confirmation. All levels ranged from 14 
to 21 μg/g. Using the known dilution factor and 
the assigned sample value, the theoretical concen-
tration of the diluted samples could be calculated. 
The diluted samples were then aliquoted, frozen 
at − 20°C and measured in 12 replicates during 3 
days, which resulted in 36 measurements for each 
concentration level in total. Biases from theoretical 
values were assessed and total error results were 
defined by the root mean square (RMS) method. 
Linearity
For defining the linearity range, a high FC sample 
was diluted with distilled water in different con-
centrations, which resulted in eleven levels in a 
range from 100% - 0%. Concentrations above the 
highest calibrator were diluted 1:10 with distilled 
Biochem Med (Zagreb) 2017;27(3):030710  https://doi.org/10.11613/BM.2017.030710 
4
Noebauer B. et al. Fully automated PETIA for faecal calprotectin
water, by the analyzer specific protocol and tested. 
All measurements were carried out in duplicates 
to calculate the deviation from the expected val-
ue. Recovery was calculated by comparing the ob-
served values with the expected values.
Precision 
For precision study, two controls and four faecal 
extracts (calprotectin concentration of the extracts 
were assigned via a value transfer protocol toward 
Bühlmann fCAL® ELISA) were measured during 20 
days, with two runs per day, and two replicates per 
run: a 20 x 2 x 2 design in accordance with CLSI 
protocol EP5-A3 (18). The coefficients of variation 
(CVs) for precision study were calculated within 
run (CVs in a single run without interruption; µg/g), 
between run (CVs between two runs per day after 
a minimum of 2 hours break; %), between days 
(CVs between days; %) and total (overall CV; %).  
Calibration curve stability
First, calibration with the Calibrator Kit was carried 
out, which comprises blood-derived human cal-
protectin and is standardized against internal ref-
erence material. For baseline values (week 0), 4 
stool extracts with validated calprotectin concen-
trations were measured 3 times in 2 runs, which re-
sulted in 6 results per extract. Subsequently, the 
four stool extracts were measured in triplicates 
every consecutive week. The mean values of the 
measured calibrators per week were compared to 
the baseline values, to calculate the recoveries 
with an acceptance of 20% deviation from base-
line. The study ended when recovery was out of 
range on two consecutive weeks.
Sample carry-over
There was no need for sample carry-over analysis 
as only disposable cuvettes and tips were used, for 
both the reagents and samples, on the clinical an-
alyzer VITROS® 5600. For that reason, the risk of 
carry-over on this analyzer is minimized.
Statistical analysis
A total number of 95 stool samples for PETIA and 
ELISA and 53 stool samples for PETIA and the semi-
quantitative assay were included for the agree-
ment assessment between the different methods. 
Concentrations above the highest calibrator were 
diluted 1:10 with distilled water. Using the mean 
concentrations calculated from the duplicate 
measurements of each sample, Passing–Bablok re-
gression analysis and Bland-Altman plots were 
performed from the PETIA with the mean concen-
tration measured by the ELISA and the semi-quan-
titative lateral flow assay using MedCalc statistical 
software version 11.6 (MedCalc, Ostend, Belgium).
Results
For the LoQ-analysis, samples in the concentration 
range of 14 to 21 µg/g were measured in 12 repli-
cates during 3 days. Limit of quantitation was de-
fined as the lowest concentration possible that 
showed a total error below 20%. The PETIA 
showed a LoQ of 21 μg/g calprotectin, on the VIT-
ROS® 5600 analyzer, with a total error of 18.98%.
For analysing the linearity of the PETIA, expected 
values were compared to the observed ones and 
recovery calculated. Results of linearity testing are 
listed in Figure 1 and confirmed linearity in the 
range from 20 - 2100 µg/g, the LoQ and the high-
est calibrator standard used. 
For precision of the assay, within run CVs (2.15% - 
6.63%), between day CV (< 0.01% - 4.72%), be-
tween run CV (< 0.01% - 6.05%) and total CV (2.33% 
- 8.89%) were calculated, details are shown in Ta-
ble 1. Therefore, the expected imprecision was be-
low 8.9% for sample concentrations between 50.6 
and 1079 µg/g. 
Calibration curve stability testing revealed that the 
calibration curve was stable for a period of 4 
weeks. The testing covered the range of expected 
results, using four different calprotectin concen-
tration levels: 50, 80, 250 and 1000 µg/g. The sam-
ples measured in week 4 showed a recovery from 
baseline between 98% and 106%. 
Analytical method agreement (Passing-Bablok re-
gression analysis) and possible systematic bias 
(Bland-Altman plot) were investigated for the fully 
automated PETIA and the ELISA (Figure 2 and 3), 
and PETIA and the semi-quantitative lateral flow 
analyzer (Figure 4 and 5). 
The Passing-Bablok linear regression analysis of the 
PETIA on VITROS® 5600 and ELISA (N = 95) showed 
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100 2113 2105 100.4
80 1720 1684 102.1
60 1209 1263 95.7
40 867 842 103.0
20 446 421 106.0
10 218 210 103.4
5 115 105 109.2
2.5 57 53 107.6
1.25 23 26 87.0
0.625 3 13 19.0
0 0 0 ND
Figure 1. Linearity testing of the fully automated particle-en-
hanced turbidimetric immunoassay (PETIA) on the VITROS® 
5600. Linearity was tested and confirmed in the range from 20 
to 2100 μg/g. ND – not detected.







y = 21.10 x + 2.72
R2 = 0.999
observed expected
Sample 1 Sample 2 Sample 3 Sample 4 Control low Control high
Mean 50.6 82.6 277.5 1078.7 77.0 243.8
Within run CV (µg/g) 6.63 2.47 0.97 0.46 5.10 2.15
Between day CV (%) < 0.01 4.72 2.81 2.82 1.35 0.90
Between run CV (%) 6.05 3.10 2.63 1.17 < 0.01 < 0.01
Total CV (%) 8.89 6.16 3.97 3.09 5.27 2.33
Four distinct sample concentrations and two controls were used for the assessment of different coefficients of variations (CVs).
Table 1. Precision data analysis for the fully automated particle-enhanced turbidimetric immunoassay (PETIA) on VITROS® 5600 
good agreement (R = 0.99), with an intercept (95% 
confidence interval, CI) of 1.53 (- 0.69 to 3.14) and a 
slope (95% CI) of 1.01 (0.99 to 1.02) (Figure 2). The FC 
concentrations of the faecal samples ranged from 0 
to 10,692 µg/g by PETIA and from 0 to 10,237 µg/g 
Figure 2. Passing-Bablok regression analysis of the fully auto-
mated particle-enhanced turbidimetric immunoassay (PETIA) 
performed on the VITROS® 5600 analyzer and an ELISA assay 
for faecal calprotectin. N = 95; concentration range: PETIA = 0 
– 10,692 µg/g, ELISA = 0 – 10,237 µg/g; Pearson correlation coef-
ficient R = 0.99; P < 0.001. Regression line equation with corre-
sponding 95% CI for intercept and slope was y = 1.53 (- 0.69 to 
3.14) + 1.01 (0.99 to 1.02) x. Cusum test for linearity indicates no 
































by ELISA. In the Bland-Altman plots mean absolute 
and relative biases with corresponding limits of 
agreement were - 3.8 (- 327.7 to 320.1) (Figure 3A) 
and 7.2% (- 104.8 to 119.2) (Figure 3B), respectively. 
The Passing-Bablok regression analysis for the PE-
TIA and the semi-quantitative lateral flow assay (N 
= 53) illustrated acceptable agreement as well (R = 
0.93), with an intercept (95% CI) of 0.35 (- 10.03 to 
7.38) and slope (95% CI) of 0.99 (0.91 to 1.08) (Fig-
ure 4). The FC concentrations of faecal samples, 
used for method validation, ranged from 0 µg/g to 
852 µg/g for the PETIA and from 31 µg/g to 820 
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Figure 3. Bland-Altman plot for (A) absolute and (B) relative differences between the automated particle-enhanced turbidimetric im-
munoassay (PETIA) on the VITROS® 5600 analyzer and an ELISA assay for faecal calprotectin. The bold solid line represents the mean 
bias, the dashed lines the upper and lower limit of agreement. The grey lines represent the 95% confidence interval.
Figure 4. Method comparison of the automated particle-en-
hanced turbidimetric immunoassay (PETIA) performed on the 
VITROS® 5600 analyzer and a semi-quantitative lateral flow assay 
for faecal calprotectin. N = 53; concentration range: PETIA 0 – 852 
µg/g, semi-quantitative lateral flow assay 31 – 820 µg/g. Pearson 
correlation coefficient R = 0.93, P < 0.001. Regression line equa-
tion with corresponding 95% CI for intercept and slope was y = 
0.35 (- 10.03 to 7.38) + 0.99 (0.91 to 1.08) x. Cusum test for linearity 
indicates no significant deviation from linearity (P = 0.28).
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µg/g for the semi-quantitative lateral flow assay. 
The Bland-Altman plot showed a mean absolute 
and relative bias with corresponding limits of 
agreement of - 0.5 (- 89.5 to 88.5) (Figure 5A) and 
0.4 % (- 90.6 to 91.4) (Figure 5B), respectively. 
Discussion
For rapid analysis of FC as a screening-parameter 
in IBD, an accurate assay with an easy, fast and 
good performance is appreciated. For that reason, 
we validated the performance of the fully auto-
mated PETIA on the VITROS® 5600 integrated sys-
tem, which is often used in paediatric laboratories 
because of its requires small sample volume (19).
Overall, the immunoassay performed well in terms 
of LoQ, linearity, precision and calibration curve 
stability. These results are in line with a recent 
study of Nilson et al. who evaluated the fully auto-
mated PETIA fCAL® turbo for the analysers Mindray 
BS-380 and Cobas c501 (20). The study showed an 
equal linearity range for all three methods and 
similar LoQs for the PETIA on the VITROS® 5600 
and the Cobas c501 with 20 µg/g (BS-380: 11 µg/g). 
The precision was found with a total coefficient of 
variation between 3% and 8% in the 50 – 100 µg/g 
range for both analysers, respectively, and is in 
agreement with our results of the PETIA on the 
VITROS® 5600. However, the BS-380 demonstrated 
stability for a period of 10 weeks, whereas the cali-
bration curve for the fully automated PETIA on 
VITROS® 5600 was stable for 4 weeks. 
For method validation, we additionally compared 
the fully automated PETIA with the most com-
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monly used ELISA assay (Bühlmann fCAL® ELISA) 
and with a POC-method (Bühlmann Quantum Blue 
Reader®). The fully automated PETIA showed good 
agreement with the ELISA, as well as with the 
semi-quantitative assay. As already pointed out, 
the standard ELISA-based methods are generally 
used as reference methods for FC measurement, 
albeit they are labour intensive, time-consuming 
and have long test-turnaround times. As a result, 
many laboratories use the point-of-care desktop 
device with its lateral flow technology. Advantage 
is the possibility of single reliable results, obtained 
in less than 30 minutes, with simplicity of sample 
preparation and analysis. However, it is a semi-
quantitative assay with a limited measurement 
range (21). In agreement with recent literature, the 
fully automated FC analysis methods turn out to 
be the future in routine laboratory work, as they 
unite short turnaround times, single sample inves-
tigation, easy as well as fast handling, a high meas-
uring range and cost-effectiveness (12,20,22). 
Two recent studies showed that using different ex-
traction devices and procedures resulted in varia-
bility between distinct assays (23,24). Hence, we 
compared all three methods using only one ex-
traction device, as all three assays are compatible 
with the same sample preparation for analysis. In 
this study, the Calex® Cap device was used for pro-
tein extraction, as it can be used with any stool 
consistency. However, De Sloovere et al. demon-
strated that the stool consistency does not affect 
FC results notably, when commercial extraction 
devices are used (22). Therefore, those devices are 
eminently suited in routine laboratory practice as 
their performance is acceptable and comparable, 
they are very easy to handle, they reduce hands-
on preparation time and weighting of stool sam-
ples can be excluded.
This is the first study investigating a fully automated 
PETIA for FC measurement on the routine analyzer 
VITROS® 5600. This procedure demonstrated an ex-
cellent overall performance and met our minimum 
demands in terms of quality standards. With its fine 
performance characteristics, its strong correlation 
with the reference method ELISA and its convenient 
handling, it is a new analytical option for the rapid 
determination of FC. Hence, it is the perfect tool for 
screening paediatric patients with gastrointestinal 
symptoms and monitoring children with IBD. 
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Figure 5. Bland-Altman plot: (A) absolute and (B) relative differences between the automated particle-enhanced turbidimetric immu-
noassay (PETIA) on the VITROS® 5600 analyzer and the semi-quantitative lateral flow assay for faecal calprotectin. The bold solid line rep-
resents the mean bias, the dashed lines the upper and lower limit of agreement. The grey lines represent the 95% confidence interval.
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